Professor Jemma C. Hopewell
BSc (Hons) MSc PhD (Cantab) FESC
Professor of Precision Medicine & Epidemiology
- British Heart Foundation IBSR Fellow
- MSc in Global Health Science Module Lead: Genetic Epidemiology
- EPSRC Centre for Doctoral Training in Health Data Science Module Lead: Genetics
- Visiting Professor, Department of Human Genetics, McGill University
Interests: Cardiovascular Disease, Genetic Epidemiology, Pharmacogenetics, Clinical Trials
Professor Jemma Hopewell leads a team of genetic epidemiologists, clinical fellows, medical statisticians and bioinformaticians in a programme of research focusing on the use of genetic and clinical trial-based studies to investigate the causes and treatments for cardiovascular disease and arrhythmias. She has particular interests in determining predictors of patient response to therapy, using genetics to improve our understanding of drug targets and disease mechanisms, and genomic characterisation of vascular disease and its risk factors, particularly Lp(a).
Jemma leads and collaborates on numerous projects involving CTSU's vascular mega-trials (e.g. HPS, SEARCH, THRIVE, REVEAL), large-scale studies and biobanks (e.g. PROCARDIS, UK Biobank), and international consortia (e.g. METASTROKE, CARDIoGRAMplusC4D, GoLEAD, CATCH-ME). She is a member of the Lp(a) Foundation Scientific Advisory Board, of various clinical trial and genetic study Steering and Analysis Committees, and is currently the Chair of METASTROKE (a collaboration of the International Stroke Genetics Consortium), as well as co-ordinating the MSc in Global Health Science Genetic Epidemiology module.
Hopewell Group - Current Members
- Research Staff
Federico Murgia, Bioinformatician
Dr Alex Stiby, Senior Genetic Epidemiologist & Statistical Programmer
Dr Elsa Valdes-Marquez, Senior Medical Statistician
Adam Von Ende, Medical Statistician
- DPhil Students
Dr Christian Camm, British Heart Foundation Clinical Research Training Fellow
Dr Parag Gajendragadkar, British Heart Foundation Clinical Research Training Fellow
Sam Smith, Personal Assistant
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet (London, England), 400, 832 - 845
Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study.
Clarke R. et al, (2022), Atherosclerosis, 354, 15 - 22
Multiplexed apolipoprotein profiling advances the assessment of residual lipid-related cardiovascular risk
Schmidt L. et al, (2022), CARDIOVASCULAR RESEARCH, 118
Are polygenic risk scores for systolic blood pressure and LDL-cholesterol associated with treatment effectiveness, and clinical outcomes among those on treatment?
Tapela NM. et al, (2022), European journal of preventive cardiology, 29, 925 - 937
Genetic associations of adult height with risk of cardioembolic and other subtypes of ischemic stroke: A mendelian randomization study in multiple ancestries.
Linden AB. et al, (2022), PLoS medicine, 19